FDA Advisory Committee Recommends Approval For Use Of GARDASIL(R) In Boys And Men

Merck & Co., Inc. announced that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee agreed that efficacy, immunogenicity and safety data from clinical trials in males support the use of GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] in boys and men 9 through 26 years of age for the prevention of genital warts caused by human papillomavirus (HPV) types 6 and 11.

Sponsored by Internet Pharmacy - Indian Pharmacy, an online pharmacy supplies more than 600 quality generic medications, free prescription, worldwide shipping.

Canadian Pharmacy canada pharmacy

Related posts:

  1. CDC Advisory Committee To Weigh Whether To Recommend Vaccinating Boys Against HPV CDC Advisory Committee To Weigh Whether To Recommend Vaccinating Boys Against HPV The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices on Wednesday is scheduled to consider...
  2. FDA Approves GARDASIL(R) For Use In Boys And Young Men FDA Approves GARDASIL(R) For Use In Boys And Young Men Merck & Co., Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved GARDASIL® [Human Papillomavirus Quadrivalent...
  3. CDC Panel Recommends HPV Vaccine Cervarix For Girls, Optional Gardasil Vaccination For Boys CDC Panel Recommends HPV Vaccine Cervarix For Girls, Optional Gardasil Vaccination For Boys The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices on Wednesday recommended GlaxoSmithKline’s human...